Generic drug manufacturers Lifestar Pharma and Chartwell Pharmaceuticals may owe refunds to 340B covered entities for overcharges on drugs purchased from the companies in the fourth quarter of 2022, according to recent notices posted on the U.S. Health Resources and
…
The U.S. Health Resources and Services Administration said late Friday that when the COVID-19 public health emergency ends on Thursday, so too will a nearly three-year-old policy clarification that lets hospitals under certain conditions dispense 340B drugs at offsite outpatient
…
Hospital group 340B Health and the American Hospital Association both have decided to support federal legislation to prohibit drug manufacturer restrictions on 340B covered entities’ use of contract pharmacies. A senior AHA official was quoted in a news article just
…
Former Republican Congressman Dan Burton (Ind.) called the 340B program “a win for all parties involved” in a Kokomo, Indiana newspaper op-ed this week and said a current House Republican’s 340B bill could deny vulnerable Hoosiers access to care.
Rep.
…
A U.S. Senate committee is attempting to mark up bipartisan legislation today to reform the pharmacy benefit management industry. The draft bill itself does not address the 340B program. Republican Sen. Mike Braun (Ind.), however, has filed an amendment for
…
A federal district judge last week declined to make federal health officials give a South Carolina health center any more documents linked to the center’s brief expulsion from and subsequent reinstatement to the 340B program in 2018.
U.S. Chief District
…
Certain flexibilities to the 340B program allowed under the COVID-19 public health emergency will expire May 11 alongside the PHE, the U.S. Health Resources and Services Administration announced Monday.
The update, which HRSA posted prominently on the Office of Pharmacy
…
Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use
…
An American Hospital Association senior executive told a U.S. House subcommittee yesterday her group opposes creating “significant new reporting requirements for 340B hospitals that do not reflect the true value or intent of the 340B program.”
But when asked by
…
The 340B program has evolved into a “buy low, sell high” drug pricing system abused by some hospitals that have profits as their main goal, a health policy researcher told lawmakers Wednesday at a U.S. House subcommittee hearing.
The House
…*Sign up for news summaries and alerts from 340B Report